Olmesartan medoxomil for the treatment of hypertension in children and adolescents

Research output: Contribution to journalArticle

Abstract

Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalVascular Health and Risk Management
Volume7
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Hypertension
Angiotensin Receptor Antagonists
Therapeutics
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Antihypertensive Agents
Olmesartan Medoxomil
Life Style
Cardiovascular Diseases
Randomized Controlled Trials
Clinical Trials
Blood Pressure
Calcium
Safety

Keywords

  • Adolescents
  • Antihypertensive treatment
  • Children
  • High blood pressure
  • Hypertension
  • Olmesartan medoxomil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{0afdbd93381f4479b6f41baff058d00e,
title = "Olmesartan medoxomil for the treatment of hypertension in children and adolescents",
abstract = "Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.",
keywords = "Adolescents, Antihypertensive treatment, Children, High blood pressure, Hypertension, Olmesartan medoxomil",
author = "Giuliano Tocci and Massimo Volpe",
year = "2011",
doi = "10.2147/VHRM.S11672",
language = "English",
volume = "7",
pages = "177--181",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Olmesartan medoxomil for the treatment of hypertension in children and adolescents

AU - Tocci, Giuliano

AU - Volpe, Massimo

PY - 2011

Y1 - 2011

N2 - Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.

AB - Prevalence of hypertension in children and adolescents has progressively and continuously increased over recent decades. Thus, early and effective control of high blood pressure may be considered an effective therapeutic approach, in order to reduce the burden of hypertension-related cardiovascular disease in future. In the past, due to the absence of prospective, long-term, randomized, controlled clinical trials performed in young hypertensive patients, lifestyle changes have been long seen as the only strategy to reduce high blood pressure levels. More recently, clinical data on the efficacy and safety of five major classes of antihypertensive drugs (including angiotensin converting enzyme inhibitors, angiotensin receptor blockers [ARBs], beta-blockers, calcium-antagonists, and diuretics) have become available. In particular, these trials demonstrated dose-dependent blood pressure reductions and a good tolerability profile of several ARBs in hypertensive children and adolescents. An overview is provided of the clinical benefits of early detection and prompt intervention of high blood pressure levels, with a closer analysis of recent clinical trials, performed with olmesartan medoxomil in young subjects with hypertension.

KW - Adolescents

KW - Antihypertensive treatment

KW - Children

KW - High blood pressure

KW - Hypertension

KW - Olmesartan medoxomil

UR - http://www.scopus.com/inward/record.url?scp=79961204130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961204130&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S11672

DO - 10.2147/VHRM.S11672

M3 - Article

C2 - 21490943

AN - SCOPUS:79961204130

VL - 7

SP - 177

EP - 181

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -